<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: It has been reported that autoimmune <z:hpo ids='HP_0001251'>cerebellar ataxias</z:hpo>, such as anti-glutamic acid decarboxylase (GAD)-antibody-positive <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> and gluten <z:hpo ids='HP_0001251'>ataxia</z:hpo>, are treatable </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we examined the therapeutic efficacy of intravenous immunoglobulin (IVIg) on autoantibody-positive <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: IVIg therapy was administered in seven autoantibody-positive <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic efficacy was examined in terms of its effects on clinical symptoms and changes in brain perfusion using single <z:chebi fb="23" ids="30212">photon</z:chebi> emission computed tomography (SPECT) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Treatment was effective in four <z:hpo ids='HP_0008278'>cerebellar cortical atrophy</z:hpo> patients (two anti-GAD antibody-positive and two anti-gliadin antibody-positive) and in one anti-thyroid antibody-positive spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) patient, but not in two multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath> (MSA) patients </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> four IVIg effective patients who underwent SPECT showed apparent increases in cerebellar perfusion </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: If <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> with an autoimmune mechanism is suspected and radiological findings do not reveal MSA, it is worth considering immunotherapy including IVIg </plain></SENT>
</text></document>